>
Switch to:

Cullinan Oncology Financial Strength

: 0 (As of Dec. 2019)
View and export this data going back to 2021. Start your Free Trial

Cullinan Oncology has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Cullinan Oncology has no debt. As of today, Cullinan Oncology's Altman Z-Score is 0.00.


Competitive Comparison

For the Biotechnology subindustry, Cullinan Oncology's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Cullinan Oncology Financial Strength Distribution

For the Biotechnology industry and Healthcare sector, Cullinan Oncology's Financial Strength distribution charts can be found below:

* The bar in red indicates where Cullinan Oncology's Financial Strength falls into.



Cullinan Oncology Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Cullinan Oncology's Interest Expense for the months ended in Dec. 2019 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2019 was $-22.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2019 was $0.00 Mil.

Cullinan Oncology's Interest Coverage for the quarter that ended in Dec. 2019 is

Cullinan Oncology had no debt.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Cullinan Oncology's Debt to Revenue Ratio for the quarter that ended in Dec. 2019 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2019 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Cullinan Oncology has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cullinan Oncology  (NAS:CGEM) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Cullinan Oncology has the Financial Strength Rank of 0.


Cullinan Oncology Financial Strength Related Terms

Thank you for viewing the detailed overview of Cullinan Oncology's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Cullinan Oncology Business Description

Cullinan Oncology logo
Industry
Healthcare » Biotechnology NAICS : 541713 SIC : 2834
Comparable Companies
Traded in Other Exchanges
N/A
Address
One Main Street, Suite 520, Cambridge, MA, USA, 02142
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Cullinan Oncology Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)